發送短信 : Health-related quality-of-life in a randomized phase III first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients from Asia with advanced NSCLC (IPASS)

 __   _      ___                _____    _    _   
| || | ||   / _ \\    ____     |  ___|| | \  / || 
| '--' ||  | / \ ||  |    \\   | ||__   |  \/  || 
| .--. ||  | \_/ ||  | [] ||   | ||__   | .  . || 
|_|| |_||   \___//   |  __//   |_____|| |_|\/|_|| 
`-`  `-`    `---`    |_|`-`    `-----`  `-`  `-`  
                     `-`